



# Portable, Accessible, and Affordable Brain Imaging

The *Swoop® Portable MR Imaging®* system is driving the future of brain health.

**March 2024**

Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.  
PROPERTY OF HYPERFINE, INC. ©2024. All rights reserved.

# Forward-looking Statements

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.



## A First for Brain Health

Hyperfine, Inc. has a unique ultra-low-field portable MR brain imaging system that aims to improve brain health globally.

- Designed to improve **access, equity, and affordability** for clinicians and patients in multiple professional healthcare settings (from critical care to offices and low-resource settings).
- Enables clinicians to make **timely and early** diagnosis of critical brain conditions.
- Potential to reduce the burden to healthcare systems of widespread and devastating **global neurological conditions**, such as stroke and **Alzheimer's disease**.



# Conventional MRI is the Clinical Gold Standard

Capacity and Availability Compromise Access and Equity Globally

High-cost and complex site requirements limit access



Need for highly trained personnel constrains capacity



Limited availability leads to delayed diagnosis and care



Inpatient transport increases risk of adverse events



# The Portable Swoop System Meets Patients and Clinicians Where and When They Need Brain Imaging

- ✓ **Diagnostic-quality** images with ultra-low-field MRI
- ✓ Safe at **multiple sites of care**
- ✓ First mover with proprietary technology (150+ patents) and **AI-powered software**
- ✓ **Platform technology** designed for multiple brain imaging applications



- ✓ **New ultra-low-field brain imaging paradigm**—disrupts access and economics and expands the MRI market
- ✓ **Broad FDA-clearance** for brain imaging of patients of all ages
- ✓ **Commercially available** in the US with reimbursement under existing CPT codes
- ✓ **Global footprint** through research institutions and the Bill & Melinda Gates Foundation funded Unity network



# The Swoop System is Transforming Brain Imaging



# Advancing the Care Value for All

Hyperfine, Inc. is at the forefront of making healthcare more connected, portable, patient-centric, and accessible in less resource-intensive settings.



## Patients

An improved, less intimidating  
MRI experience and  
simplified care navigation.



## Clinicians and Care Teams

Timely and early decisions  
and personalized  
care at their disposal.




## Hospitals

Optimizing MRI resources  
to drive efficiencies, treatment  
throughput, and  
cost reductions.

# Blueprint for Growth

The Swoop System Expands the Fast-growing \$35B<sup>1</sup> Global Imaging Market





# MRI at the Center of Promising Alzheimer's Solutions Globally

*Plasma Biomarkers, ATT to Drive Much Needed CARE Change for Alzheimer's*

## Dementia and Alzheimer's Disease<sup>1,2</sup>

**152 Million**

people in the world suffering  
from dementia estimated by 2050

**Over 50%**

of dementia cases are  
Alzheimer's disease

**>\$1.3 Trillion**

estimated global  
costs of dementia

## The Swoop System for Alzheimer's

*FDA Approval of Amyloid Targeting  
Therapies (ATT) Requires MRI Monitoring*

- ✓ FDA-cleared for brain imaging. No new FDA clearance required.
- ✓ Significant value in simplifying MRI monitoring workflow.
- ✓ Ready to address the access and equity challenges of global Alzheimer's care.



# Alzheimer's in the News

## Health Care Systems Struggle to Meet Demands of Game-Changing Treatments



The NEW ENGLAND  
JOURNAL of MEDICINE

### Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease

Randall J. Bateman, M.D., Janice Smith, Ph.D., Michael C. Donohue, Ph.D., Paul Delmar, Ph.D., Rachid Abbas, M.D., Ph.D., Stephen Salloway, M.D., Ph.D., Jakub Wojtowicz, M.Pharm., Kaj Blennow, Ph.D., Tobias Bittner, Ph.D., Sandra E. Black, M.D., Gregory Klein, Ph.D., Mercè Boada, M.D., [et al.](#), for the GRADUATE I and II Investigators and the Gantenerumab Study Group<sup>1</sup>

### Lecanemab in Early Alzheimer's Disease

Christopher H. van Dyck, M.D., Chad J. Swanson, Ph.D., Paul Aisen, M.D., Randall J. Bateman, M.D., Christopher Chen, B.M., B.Ch., Michelle Gee, Ph.D., Michio Kanekiyo, M.S., David Li, Ph.D., Larisa Reyderman, Ph.D., Sharon Cohen, M.D., Lutz Froelich, M.D., Ph.D., Sadao Katayama, M.D., [et al.](#)

### Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer's Disease

Ali R. Rezai, M.D., Pierre-Francois D'Haese, Ph.D., Victor Finomore, Ph.D., Jeffrey Carpenter, M.D., Manish Ranjan, M.B., B.S., Kirk Wilhelmsen, M.D., Rashi I. Mehta, M.D., Peng Wang, Ph.D., Umer Najib, M.D., Camila Vieira Ligo Teixeira, Ph.D., Tasneem Arsiwala, Ph.D., Abdul Tarabishy, M.D., [et al.](#)



### Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial



HEALTHY RETURNS

### Healthy Returns: The launch of breakthrough Alzheimer's drug Leqembi is off to a slow start



### NHS not ready for new Alzheimer's drugs lecanemab and donanemab, warns charity

The Washington Post  
*Democracy Dies in Darkness*

### New Alzheimer's drugs bring hope. But not equally for all patients.

The medications have not been widely tested in Black people with the disease, underscoring stark — and persistent — disparities

# Potential to Reduce Barriers to Accessible and Equitable Alzheimer's Care

## Current Paradigm



Treatments at infusion centers; imaging done separately at MRI suite.

## New Paradigm

HYPERFINE.




~3600 Infusion Centers


~2400 Clinics

The Swoop system to offer a more convenient imaging option, allowing patients to receive brain scans outside of the conventional MRI suite, simplifying care navigation for patients and care partners.


# Our Roadmap to Expanding Swoop System Use in Alzheimer's Care



## Execution Through Three Strategic Pillars



# Innovation: Proven Regular Cadence of Product Releases





# Clinical Evidence: Large and Growing Body of Published Data to Date; Significant Investment in Studies to Drive Evidence in New Use Cases

## Current Commercial and Clinical Applications



Critical Care



Pediatrics

13

publications

HOPE PMR (Hydrocephalus)  
SAFE MRI (ECMO)

## Clinical Research for Future Applications



Stroke



Alzheimer's

16

publications

Prospective Studies

ACTION PMR (Stroke)  
CARE PMR (Alzheimer's)

## Future Opportunities



Remote Care




New Use Cases

8

publications

# Commercialization: US Direct Sales and Global Market Launches



## Today



US direct sales team with distributors in Canada, Australia, New Zealand, and Pakistan

## Next 12 Months



European Union expansion

## > 12 Months



Global expansion

# Strong & Lean Financial Profile

## Strong Revenue Growth



**\$11M 2023 Revenue**

**>60% Growth:**

- Expanding use cases
- Growing body of clinical evidence
  - Skilled commercial team
  - Strategic price increases

## Healthy Gross Margins



**43% 2023 Gross Margin %**

**30% GM% Expansion:**

- Increase in average selling price
- Demonstrating significant expansion with scale

## Spending Discipline



**\$42M 2023 Cash Burn**

**>40% Reduction:**

- Over \$75M in cash and cash equivalents at year-end 2023
- Cash runway into early 2026

## 2024 Guidance:

**\$12-15M  
2024 Revenue**

**45-50%  
2024 Gross Margin**

**~\$40M  
2024 Cash Burn**

# Leadership Team With Proven Track Record of Success



**Maria Sainz**

President and Chief  
Executive Officer



**Tom Teisseyre**

Chief Operating Officer



**Brett Hale**

Chief Administrative Officer  
and Chief Financial Officer

# The Hyperfine, Inc. Opportunity



**First FDA-cleared** portable ultra-low-field AI-powered MR brain imaging system with strong proprietary technology



Commercial stage company **expanding the brain imaging market** to solve large unmet clinical/provider need globally



**Prolific engine** of fast innovation and clinical evidence



**Growth blueprint** driven by new brain MRI **access and equity** paradigm with near opportunity in **Alzheimer's**



**Solid financial profile** with rapid topline and gross margin growth and healthy cash runway



Highly experienced **executive team** with deep industry expertise



Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

PROPERTY OF HYPERFINE, INC. ©2024. All rights reserved.